US 12,343,454 B2
Hydrogels formed in situ and composition design for intrauterine use
Michael Bassett, Hampton, NH (US); and Ian Feldberg, Sudbury, MA (US)
Assigned to Pramand LLC, Bedford, MA (US)
Filed by Pramand LLC, Bedford, MA (US)
Filed on Nov. 9, 2021, as Appl. No. 17/522,727.
Application 17/522,727 is a continuation in part of application No. 17/494,752, filed on Oct. 5, 2021.
Claims priority of provisional application 63/113,013, filed on Nov. 12, 2020.
Prior Publication US 2022/0143276 A1, May 12, 2022
Int. Cl. A61L 31/14 (2006.01); A61L 31/04 (2006.01); A61L 31/18 (2006.01)
CPC A61L 31/145 (2013.01) [A61L 31/041 (2013.01); A61L 31/18 (2013.01); A61L 2300/424 (2013.01); A61L 2300/802 (2013.01)] 36 Claims
OG exemplary drawing
 
1. A medical hydrogel system comprising:
a precursor blend solution comprising an aqueous solvent, a first precursor having a hydrophilic core and succinimidyl ester functional groups, and a second precursor having a plurality of amine functional groups, wherein the precursor blend solution has an acid pH and is stable for at least about five minutes; and
an accelerator solution comprising a buffer solution having a pH from greater than 8.2 to 12, wherein a mixture of the precursor blend solution and the accelerator solution has a pH of more than 8 and a weight percent solids from about 3% to about 20% and forms a product hydrogel.